Cargando…
Vorinostat in solid and hematologic malignancies
Vorinostat (Zolinza(®)), a histone deacetylase inhibitor, was approved by the US Food and Drug Administration in October 2006 for the treatment of cutaneous manifestations in patients with cutaneous T-cell lymphoma who have progressive, persistent or recurrent disease on or following two systemic th...
| Autores principales: | , , , , , , , , |
|---|---|
| Formato: | Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2009
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2731787/ https://www.ncbi.nlm.nih.gov/pubmed/19635146 http://dx.doi.org/10.1186/1756-8722-2-31 |